On January 6, 2022, Eikon Therapeutics, Inc. closed the transaction. The company received $517,764,779 from 43 investors. The transaction included participation from funds and accounts advised by new investors T. Rowe Price Associates, Inc., Canada Pension Plan Investment Board, EcoR1 Capital, LLC, UC Investments, Abu Dhabi Investment Authority, StepStone Group Inc., Soros Capital Management LLC, Schroders Capital, Harel Insurance Co.

Ltd, Investment Arm, General Catalyst, E15 VC, Hartford HealthCare Endowment, LLC, and AME Cloud Ventures, LLC. The transaction included participation from existing investors The Column Group LLC, Foresite Capital Management, LLC, Innovation Endeavors LLC, Lux Capital Management, LLC, and Horizons Ventures Limited. The company has raised more than $668,000,000 in funding till date.